Work

Early Results of a Phase II Study Adding Peri-Transplant Rituximab to Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients (PTS) with High-Risk Fludarabine-Refractory Chronic Lymphocytic Leukemia (Cll)

Year: 2012

Type: article

Abstract: CLL pts who are fludarabine-refractory or possess unfavorable cytogenetics have short survivals with conventional therapies. Nonmyeloablative allogeneic HCT may provide long-term disease control. Disease progression is the major risk within the first year after HCT (median 3.3 months), until development of graft-versus-leukemia (GVL) effects. Treatment with anti-CD20 monoclonal antibody (rituximab) in the early post-transplant period could improve disease control: 1) directly by antibody-dependent cytotoxicity and 2) indirectly by promoting cross-presentation of cell-derived peptides causing earlier and/or more robust GVL effects.

Source: Transplantation and Cellular Therapy

Authors: M.L. Sorror, B. Storer, B.M. Sandmaier, T. Chauncey, B. Bruno, N.N.S. Andersen, W.J. Hogan, R. Storb, D. Maloney

Institutions: University of Washington, Fred Hutch Cancer Center, United States Department of Veterans Affairs, University of Turin, Rigshospitalet, Mayo Clinic

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650

OpenAlex ID: W1998480724

FWCI:

Cites:

Cited by:

Related to: 10